Skip to content
BiologicalX

Comparison

Alpha-GPC vs Vitamin D3 + K2

Side-by-side of Alpha-GPC and Vitamin D3 + K2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-GPC

  • Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
  • Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
  • Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
  • ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
  • Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
  • TMAO production raises a contested cardiovascular concern at chronic high doses

Vitamin D3 + K2

  • Reduces non-vertebral fractures 10-20% in older adults at 800 IU/day or above when combined with calcium
  • VITAL trial showed neutral results on primary CV and cancer endpoints at 2000 IU/day over 5 years
  • Vitamin D supplementation reduces respiratory infection incidence ~10-20% in deficient populations
  • K2 MK-7 has 72-hour plasma half-life vs 1-2 hours for MK-4; once-daily dosing is sufficient
  • Synergy hypothesis is largely preclinical; dedicated combination RCTs are limited
  • Daily dosing outperforms bolus dosing for immune and infection outcomes

Side-by-side

Attribute Alpha-GPC Vitamin D3 + K2
Category supplement supplement
Also known as L-Alpha glycerylphosphorylcholine, choline alfoscerate, GPC, alpha-glyceryl phosphorylcholine cholecalciferol + menaquinone, D3/K2, vitamin D3 with MK-7
Half-life (hr) 4 360
Typical dose (mg) 600 0.05
Dosing frequency 1 to 3 times daily daily with a fat-containing meal
Routes oral oral
Onset (hr) 1 24
Peak (hr) 2 168
Molecular weight 257.22 384.64
Molecular formula C8H20NO6P C27H44O (D3); C46H64O2 (MK-7)
Mechanism Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS. D3 converts to calcidiol then calcitriol, activating the vitamin D receptor (VDR) to increase intestinal calcium absorption and modulate immune and bone gene transcription. K2 carboxylates osteocalcin and matrix Gla protein, directing calcium toward bone and inhibiting vascular calcification.
Legal status Dietary supplement (US); prescription medication in much of Europe Dietary supplement (global)
WADA status allowed allowed
DEA / Rx OTC supplement Not scheduled
Pregnancy Insufficient data; choline generally recommended in pregnancy Recommended at standard doses for fetal bone development; consult clinician at higher doses
CAS 28319-77-9 67-97-0
PubChem CID 71920 5280795
Wikidata Q411478 Q139347

Safety profile

Alpha-GPC

Common side effects

  • mild GI upset
  • headache
  • dizziness
  • occasional insomnia with evening dosing

Contraindications

  • established cardiovascular disease (TMAO concern)
  • concurrent strong anticholinergic therapy

Interactions

  • anticholinergic medications: partial mutual antagonism(minor)
  • cholinesterase inhibitors (donepezil): additive cholinergic effect, basis for ASCOMALVA protocol(minor)
  • scopolamine: partial counteraction of anticholinergic effect(minor)

Vitamin D3 + K2

Common side effects

  • GI upset at high doses
  • headache (rare)
  • hypercalcemia (only at sustained very high D3 doses)

Contraindications

  • hypercalcemia
  • sarcoidosis
  • active hyperparathyroidism
  • warfarin therapy (K2 component requires stable intake)

Interactions

  • warfarin: K2 component can affect anticoagulation; maintain stable intake and inform anticoagulation clinic(moderate)
  • thiazide diuretics: additive calcium retention; hypercalcemia risk with high-dose D3(moderate)
  • digoxin and calcium channel blockers: additive effects from D3-induced hypercalcemia(moderate)
  • glucocorticoids: reduced vitamin D efficacy and bone effects(moderate)
  • cholestyramine and orlistat: bind fat-soluble vitamins; separate dosing by 2 to 4 hours(moderate)

Which Should You Take?

Vitamin D3 + K2 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Alpha-GPC is the right call when one of the conditionals below applies.

  • If your priority is focus or working memory, pick Alpha-GPC.
  • If your priority is athletic performance, pick Alpha-GPC.
  • If your priority is bone density, pick Vitamin D3 + K2.
  • If your priority is healthspan extension, pick Vitamin D3 + K2.

Edge case: Half-lives differ materially (Alpha-GPC ~4 hr vs Vitamin D3 + K2 ~360 hr). Vitamin D3 + K2 reaches steady state faster; Alpha-GPC is easier to dial in if tolerability is uncertain.

Default choice: Vitamin D3 + K2. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Alpha-GPC only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-GPC and Vitamin D3 + K2?

Alpha-GPC and Vitamin D3 + K2 differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-GPC or Vitamin D3 + K2?

Alpha-GPC half-life is 4 hours; Vitamin D3 + K2 half-life is 360 hours.

Can you stack Alpha-GPC with Vitamin D3 + K2?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper